Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Clinical evidence and trial services

SubmarketREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Clinical evidence and trial services

Clinical-trial design, patient and site management, monitoring, data management and evidence-generation services supporting regulatory submissions and payer coverage.

Market size
$3.2B
$3.2B ($2.1B–$4.6B) · 2025 · Triangulated
Growth
+7.0%
$10.6B by 2034
Attractiveness
75 /100
for B2B sellers
Evidence
Medium confidence
1 source · Triangulated
Level
Submarket
Segmented by
Product or service
Buyers
Medical-device, diagnostic and digital-health vendors, pharmaceutical and biotechnology companies
Buying centre
Clinical affairs, medical affairs, research and development, procurement, finance
Maturity
Growth
Structure
Fragmented
Buying triggers
  • PMA submission requiring pivotal data
  • Payer coverage request requiring comparative clinical evidence
  • Post-market surveillance study commitments
  • New indication expansion requiring new evidence
Pains
  • Slow site recruitment and enrolment
  • Fragmented data across sites and systems
  • Evidence packages that do not satisfy regulators or payers
  • High cost per patient enrolled
Scores (1–5)
Pain intensity4
Purchasing power3
Reachability4
Growth4
Growth drivers
  • Evidence requirements for device approval and payer coverage [1][2]
  • PMA and confirmatory clinical evidence needs for higher-risk devices
  • Real-world evidence and post-market data generation for reimbursement
  • Digital-health and software-as-medical-device validation studies
Headwinds
  • Medtech trial budgets highly sensitive to capital-market conditions
  • CRO capacity and investigator-site scarcity raising prices
  • Long timelines that can be deferred by sponsors
Trends
  • Decentralised and hybrid trial execution for device studies
  • eClinical and real-world evidence platforms [1]
  • Smaller, adaptive and pragmatic device study designs
  • Evidence generation shifting earlier in product development

Niches 4

Split by customer type.

Niche

Pharma and biotech outsourced clinical development

Pharmaceutical and biotechnology companies that outsource protocol design, patient and site management, monitoring, data management and regulatory-submission evidence across the cl

$63.6B
Pharmaceutical and biotechnology sponsors
Medium confidenceOpen

How this was sized

$3.2B ($2.1B–$4.6B) · 2025 · Triangulated

CRO/clinical trial services are USD 57.5-59.6B in 2025 growing to about USD 106B by 2033-2035 at 6.5-7.5% [1]. Medtech and diagnostics vendors are a minority of CRO spend (most is pharma); a 5-8% share is assumed for medtech/diagnostics/digital-health buyers, giving USD 2.9-4.8B, and a USD 3.2B midpoint for 2025. Forecast scaled at the 6.5-7.5% market growth rate [1].

Alongside it in Clinical and regulatory support services

// Sell into Clinical evidence and trial services

AOS finds the biggest accounts in this submarket with a reason to talk now, maps their buying centre and prepares the outreach for your approval.